Evidence Level:Sensitive: A2 - Guideline
New
Excerpt:HER2-Negative and postmenopausal or premenopausal receiving ovarian ablation or suppression: Preferred Regimens: Second and subsequent line therapy: Everolimus + endocrine therapy (exemestane, fulvestrant, tamoxifen).
Secondary therapy:fulvestrant; exemestane; tamoxifen
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Excerpt:...HER2 is negative if a single test (or all tests) performed in a tumor specimen show: 1....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Everolimus TDM to Predict Long Term Toxicity
Excerpt:...- Patients currently treated with everolimus for any type of cancer, such as the EMA registered indications i.e. advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer, metastatic renal cell carcinoma (mRCC) or neuroendocrine tumour (NET) of pancreatic, gastrointestinal or lung origin....
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Excerpt:...- Postmenopausal advanced hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer after failure of treatment with letrozole or anastrozole...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women
Excerpt:...Histological or cytological confirmation of estrogen-receptor positive (ER+), HER2 negative breast cancer....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Excerpt:...- Patients must have a histologically confirmed diagnosis of hormone receptor positive, HER2 negative invasive breast carcinoma....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
Excerpt:...- Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human Epidermal Growth Factor Receptor-2)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
Excerpt:...- Patients affected of a breast cancer advanced andor metastatic HER2 negative expressing the hormonal receptor RH +...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Excerpt:...HER2-negative breast cancer, defined as follows:...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A randomized controlled trial for Neoadjuvant Everolimus Plus EC followed by T Compared With EC followed by T in patients with ER-positive, HER2-negative operable breast cancer
Excerpt:...No distant metastasis by histological diagnosis of histological grade level III of invasive breast cancer patients (T > 2 cm, or any T and histological diagnosis of metastatic axillary lymph node > 2 cm), tumor molecular diagnosis of ER positive immunohistochemical study (ER positive percentage of 10% or higher), her2-negative (HER2 immunohistochemical staining 0 or 1 + or fluorescence in situ hybridization FISH -); 3. ...
